Literature DB >> 410579

Kinetics of oral ethambutol in the normal subject.

C S Lee, J G Gambertoglio, D C Brater, L Z Benet.   

Abstract

Six normal adult volunteers received 15 mg/kg of ethambutol (EMB) by mouth, once as an aqueous solution and again as the commercial tablet preparation. Each dose was separated by at least 7 days. Plasma and urine samples were collected at regular intervals for up to 24 and 72 hr, respectively. Peak plasma concentrations ranged from 3.25 to 5.62 mcg/ml, 2 to 4 hr after tablet dosage. Earlier peak times were found after administering the solution. For plasma concentrations up to 12 hr there was a distinct distribution phase followed by an apparent elimination phase with a mean half-life (t 1/2) (+/- SD) of 4.06 +/- 0.53 and 4.78 +/- 0.41 hr for the tablet and the solution, respectively. Excretion rate plots exhibited similar t 1/2 values for the apparent elimination phase. An even longer t 1/2 of approximately 10 hr was evident from 24-hr plasma samples and urinary excretion measurements up to 72 hr. Unchanged drug excreted in the urine averaged 61.1 +/- 3.8% of the dose for the tablet and 63.4 +/- 2.6% for the solution. Plasma protein binding for ethambutol determined by equilibrium dialysis and ultrafiltration was approximately 20% to 30%. The concentration ratio of ethambutol in erythrocytes to plasma ranged from 1.1 to 1.6.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 410579     DOI: 10.1002/cpt1977225part1615

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

1.  The management of tuberculous meningitis.

Authors:  M Humphries
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

2.  Protein Binding of First-Line Antituberculosis Drugs.

Authors:  Wael A Alghamdi; Mohammad H Al-Shaer; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

4.  Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.

Authors:  Claire Andréjak; Deepak V Almeida; Sandeep Tyagi; Paul J Converse; Nicole C Ammerman; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

5.  Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo.

Authors:  Claudia Plinke; Kerstin Walter; Sahar Aly; Stefan Ehlers; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

6.  Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.

Authors:  Shashikant Srivastava; Sandirai Musuka; Carleton Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

Review 7.  The pharmacological role of the kidney.

Authors:  D C Brater
Journal:  Drugs       Date:  1980-01       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 9.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

10.  Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake.

Authors:  M Masud Parvez; Jin Ah Jung; Ho Jung Shin; Dong Hyun Kim; Jae-Gook Shin
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.